Association between toxic drug events and encephalopathy in British Columbia, Canada: a cross-sectional analysis.
Addiction Medicine
Brain Injury
Drug overdose
Encephalopathy
Epidemiology
Opioid
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
28
04
2023
accepted:
03
06
2023
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Encephalopathy can occur from a non-fatal toxic drug event (overdose) which results in a partial or complete loss of oxygen to the brain, or due to long-term substance use issues. It can be categorized as a non-traumatic acquired brain injury or toxic encephalopathy. In the context of the drug toxicity crisis in British Columbia (BC), Canada, measuring the co-occurrence of encephalopathy and drug toxicity is challenging due to lack of standardized screening. We aimed to estimate the prevalence of encephalopathy among people who experienced a toxic drug event and examine the association between toxic drug events and encephalopathy. Using a 20% random sample of BC residents from administrative health data, we conducted a cross-sectional analysis. Toxic drug events were identified using the BC Provincial Overdose Cohort definition and encephalopathy was identified using ICD codes from hospitalization, emergency department, and primary care records between January 1st 2015 and December 31st 2019. Unadjusted and adjusted log-binomial regression models were employed to estimate the risk of encephalopathy among people who had a toxic drug event compared to people who did not experience a toxic drug event. Among people with encephalopathy, 14.6% (n = 54) had one or more drug toxicity events between 2015 and 2019. After adjusting for sex, age, and mental illness, people who experienced drug toxicity were 15.3 times (95% CI = 11.3, 20.7) more likely to have encephalopathy compared to people who did not experience a drug toxicity event. People who were 40 years and older, male, and had a mental illness were at increased risk of encephalopathy. There is a need for collaboration between community members, health care providers, and key stakeholders to develop a standardized approach to define, screen, and detect neurocognitive injury related to drug toxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Encephalopathy can occur from a non-fatal toxic drug event (overdose) which results in a partial or complete loss of oxygen to the brain, or due to long-term substance use issues. It can be categorized as a non-traumatic acquired brain injury or toxic encephalopathy. In the context of the drug toxicity crisis in British Columbia (BC), Canada, measuring the co-occurrence of encephalopathy and drug toxicity is challenging due to lack of standardized screening. We aimed to estimate the prevalence of encephalopathy among people who experienced a toxic drug event and examine the association between toxic drug events and encephalopathy.
METHODS
METHODS
Using a 20% random sample of BC residents from administrative health data, we conducted a cross-sectional analysis. Toxic drug events were identified using the BC Provincial Overdose Cohort definition and encephalopathy was identified using ICD codes from hospitalization, emergency department, and primary care records between January 1st 2015 and December 31st 2019. Unadjusted and adjusted log-binomial regression models were employed to estimate the risk of encephalopathy among people who had a toxic drug event compared to people who did not experience a toxic drug event.
RESULTS
RESULTS
Among people with encephalopathy, 14.6% (n = 54) had one or more drug toxicity events between 2015 and 2019. After adjusting for sex, age, and mental illness, people who experienced drug toxicity were 15.3 times (95% CI = 11.3, 20.7) more likely to have encephalopathy compared to people who did not experience a drug toxicity event. People who were 40 years and older, male, and had a mental illness were at increased risk of encephalopathy.
CONCLUSIONS
CONCLUSIONS
There is a need for collaboration between community members, health care providers, and key stakeholders to develop a standardized approach to define, screen, and detect neurocognitive injury related to drug toxicity.
Identifiants
pubmed: 37420239
doi: 10.1186/s13011-023-00544-z
pii: 10.1186/s13011-023-00544-z
pmc: PMC10329314
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Informations de copyright
© 2023. The Author(s).
Références
MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):76-79
pubmed: 28125568
Neurocrit Care. 2010 Aug;13(1):93-7
pubmed: 20440598
Neurocase. 2013 Aug;19(4):313-5
pubmed: 22624985
Neuroradiol J. 2020 Jun;33(3):267-270
pubmed: 32508271
Int J Drug Policy. 2021 Nov;97:103362
pubmed: 34314956
Can J Neurol Sci. 2020 May;47(3):398-399
pubmed: 32063243
Front Neurol. 2018 Aug 27;9:708
pubmed: 30210433
J Clin Neurosci. 2012 Jul;19(7):1060-2
pubmed: 22555127
AJNR Am J Neuroradiol. 2006 Sep;27(8):1763-5
pubmed: 16971632
Neurochem Int. 2021 Feb;143:104936
pubmed: 33309980
Front Neurol. 2017 Feb 08;8:27
pubmed: 28228745
PLoS One. 2019 Jan 10;14(1):e0210129
pubmed: 30629607
Front Neurol. 2020 Feb 12;10:1420
pubmed: 32116991
Harm Reduct J. 2011 Jan 21;8:3
pubmed: 21255414
N Engl J Med. 2018 Mar 22;378(12):1157-1158
pubmed: 29562161
J Child Neurol. 2010 Jun;25(6):748-51
pubmed: 19808992
J Intensive Care Soc. 2019 Feb;20(1):80-85
pubmed: 30792768
J Clin Neurosci. 2001 Mar;8(2):165-7
pubmed: 11243768
Clin Case Rep. 2020 Feb 28;8(4):635-639
pubmed: 32274025
BMJ Open. 2019 May 5;9(5):e025567
pubmed: 31061028
J Clin Psychopharmacol. 2012 Aug;32(4):503-10
pubmed: 22722510